Posts by: Joana Carvalho

News

CT053, one of CARsgen Therapeutics‘ lead CAR T-cell therapies, soon will begin clinical testing in China for the treatment of patients with relapsed or refractory multiple myeloma, after the Chinese ... Read more

March 8, 2019

FDA Raises Concerns on Safety, Tolerability of Potential Myeloma Therapy Selinexor

News

The U.S. Food and Drug Administration has raised concerns in its newly released briefing materials over the safety and tolerability of Karyopharm Therapeutics‘ lead compound selinexor, creating a potential stumbling block on its path ... Read more

October 26, 2018October 26, 2018

Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show

News

Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time until disease progression in patients with smoldering multiple myeloma who were not yet experiencing any symptoms of disease, according to Phase 2/3 results ... Read more

October 24, 2018

Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows

News

Adding Darzalex (daratumumab) to the standard pre-transplant therapy for multiple myeloma significantly increased the number of patients showing no signs of cancer after a stem cell transplant, a Phase ... Read more

October 8, 2018

Takeda, Molecular Templates Partner to Develop Next-generation IO for Multiple Myeloma

News

Molecular Templates has partnered with Takeda to develop engineered toxin bodies (EBTs) — a next-generation immuno-oncology therapy that delivers toxic payloads to cancer cells — targeting the CD38 molecule as a potential treatment for multiple myeloma. ... Read more

September 10, 2018

Some with Smoldering Multiple Myeloma May Benefit from Immediate Treatment, Study Suggests

News

Smoldering multiple myeloma (SMM) — an early, asymptomatic precursor of multiple myeloma — often exhibits similar genetic alterations as the full-blown disease, suggesting that patients could benefit from prompt treatment instead ... Read more

August 1, 2018

Machine-learning Algorithm Predicts Responses to Myeloma Treatments

News

Inserting data from genetically similar patients into a machine-learning algorithm may help predict which multiple myeloma patients will benefit from Velcade (bortezomib) or Revlimid (lenalidomide) treatment, a study shows. Those findings ... Read more

July 20, 2018

Dendritic Cell Vaccine in Immunotherapy Triple Combo Seen to Boost Immune Response to Myeloma in Early Study

News

A triple combination treatment — dendritic cell vaccination plus Revlimid (lenalidomide) and an anti-PD-1 checkpoint inhibitor — led to stronger anti-tumor immune responses against myeloma in mice, a study reports. ... Read more

Posts by: Joana Carvalho

Joana Carvalho

CARsgen to Begin CT053 Clinical Testing in China for Heavily Treated Myeloma Patients

FDA Raises Concerns on Safety, Tolerability of Potential Myeloma Therapy Selinexor

Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show

Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows

Takeda, Molecular Templates Partner to Develop Next-generation IO for Multiple Myeloma

Some with Smoldering Multiple Myeloma May Benefit from Immediate Treatment, Study Suggests

Machine-learning Algorithm Predicts Responses to Myeloma Treatments

Dendritic Cell Vaccine in Immunotherapy Triple Combo Seen to Boost Immune Response to Myeloma in Early Study

Pin It on Pinterest